Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Medtronic
Express Scripts
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TEMSIROLIMUS

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Temsirolimus

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 2001-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed University of Texas Phase 1 2001-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
NCT00003712 CCI-779 in Treating Patients With Advanced Solid Tumors Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2001-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of CCI-779 in treating patients who have advanced solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Temsirolimus

Condition Name

Condition Name for Temsirolimus
Intervention Trials
Renal Cell Carcinoma 13
Advanced Cancer 10
Unspecified Adult Solid Tumor, Protocol Specific 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Temsirolimus
Intervention Trials
Carcinoma 47
Carcinoma, Renal Cell 41
Lymphoma 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Temsirolimus

Trials by Country

Trials by Country for Temsirolimus
Location Trials
United States 924
Canada 88
Germany 37
France 29
Australia 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Temsirolimus
Location Trials
Texas 57
California 45
New York 42
Pennsylvania 39
Illinois 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Temsirolimus

Clinical Trial Phase

Clinical Trial Phase for Temsirolimus
Clinical Trial Phase Trials
Phase 4 3
Phase 3 8
Phase 2 90
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Temsirolimus
Clinical Trial Phase Trials
Completed 102
Active, not recruiting 42
Terminated 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Temsirolimus

Sponsor Name

Sponsor Name for Temsirolimus
Sponsor Trials
National Cancer Institute (NCI) 81
Pfizer 31
Wyeth is now a wholly owned subsidiary of Pfizer 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Temsirolimus
Sponsor Trials
Other 167
Industry 100
NIH 82
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Baxter
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.